Texas children's medication algorithm project

Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder

Carroll W. Hughes, Graham J. Emslie, M. Lynn Crismon, Kelly Posner, Boris Birmaher, Neal Ryan, Peter Jensen, John Curry, Benedetto Vitiello, Molly Lopez, Steve P. Shon, Steven R. Pliszka, Madhukar H. Trivedi, Joan Barcelona, Cindy Hopkins, Peter S. Jensen, Robin Mallett, Sylvia Musquiz, Valerie Robinson, Susan Rogers & 3 others Steve Shon, Madhukar Trivedi, Sylvia Turner

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

OBJECTIVE: To revise and update consensus guidelines for medication treatment algorithms for childhood major depressive disorder based on new scientific evidence and expert clinical consensus when evidence is lacking. METHOD: A consensus conference was held January 13-14, 2005, that included academic clinicians and researchers, practicing clinicians, administrators, consumers, and families. The focus was to review, update, and incorporate the most current data to inform and recommend specific pharmacological approaches and clinical guidance for treatment of major depressive disorder in children and adolescents. RESULTS: Consensually agreed on medication algorithms for major depression (with and without psychosis) and comorbid attention-deficit disorders were updated. These revised algorithms also incorporated approaches to address issues of suicidality, aggression, and irritability. Stages 1, 2, and 3 of the algorithm consist of selective serotonin reuptake inhibitor and norepinephrine serotonin reuptake inhibitor medications whose use is supported by controlled, acute clinical trials and clinical experience. Recent studies provide support that selective serotonin reuptake inhibitors in addition to fluoxetine are still encouraged as first-line interventions. The need for additional assessments, precautions, and monitoring is emphasized, as well as continuation and maintenance treatment. CONCLUSIONS: Evidence and expert clinical consensus support the use of selected antidepressants in the treatment of depression in youths. The use of the recommended antidepressant medications requires appropriate monitoring of suicidality and potential adverse effects and consideration of other evidence-based treatment alternatives such as cognitive behavioral therapies. Copyright 2007

Original languageEnglish (US)
Pages (from-to)667-686
Number of pages20
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume46
Issue number6
DOIs
StatePublished - Jun 2007
Externally publishedYes

Fingerprint

Major Depressive Disorder
Consensus
Serotonin Uptake Inhibitors
Antidepressive Agents
Depression
Therapeutics
Needs Assessment
Fluoxetine
Controlled Clinical Trials
Cognitive Therapy
Attention Deficit Disorder with Hyperactivity
Administrative Personnel
Aggression
Psychotic Disorders
Research Personnel
Pharmacology
Guidelines

Keywords

  • Child and adolescent depression
  • Childhood psychopharmacology
  • Major depressive disorder
  • Medication algorithm
  • Suicidality

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Texas children's medication algorithm project : Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. / Hughes, Carroll W.; Emslie, Graham J.; Crismon, M. Lynn; Posner, Kelly; Birmaher, Boris; Ryan, Neal; Jensen, Peter; Curry, John; Vitiello, Benedetto; Lopez, Molly; Shon, Steve P.; Pliszka, Steven R.; Trivedi, Madhukar H.; Barcelona, Joan; Hopkins, Cindy; Jensen, Peter S.; Mallett, Robin; Musquiz, Sylvia; Robinson, Valerie; Rogers, Susan; Shon, Steve; Trivedi, Madhukar; Turner, Sylvia.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 46, No. 6, 06.2007, p. 667-686.

Research output: Contribution to journalArticle

Hughes, CW, Emslie, GJ, Crismon, ML, Posner, K, Birmaher, B, Ryan, N, Jensen, P, Curry, J, Vitiello, B, Lopez, M, Shon, SP, Pliszka, SR, Trivedi, MH, Barcelona, J, Hopkins, C, Jensen, PS, Mallett, R, Musquiz, S, Robinson, V, Rogers, S, Shon, S, Trivedi, M & Turner, S 2007, 'Texas children's medication algorithm project: Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 46, no. 6, pp. 667-686. https://doi.org/10.1097/chi.0b013e31804a859b
Hughes, Carroll W. ; Emslie, Graham J. ; Crismon, M. Lynn ; Posner, Kelly ; Birmaher, Boris ; Ryan, Neal ; Jensen, Peter ; Curry, John ; Vitiello, Benedetto ; Lopez, Molly ; Shon, Steve P. ; Pliszka, Steven R. ; Trivedi, Madhukar H. ; Barcelona, Joan ; Hopkins, Cindy ; Jensen, Peter S. ; Mallett, Robin ; Musquiz, Sylvia ; Robinson, Valerie ; Rogers, Susan ; Shon, Steve ; Trivedi, Madhukar ; Turner, Sylvia. / Texas children's medication algorithm project : Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2007 ; Vol. 46, No. 6. pp. 667-686.
@article{13bf5dfa6bab4610bea2ce0c818dfd6e,
title = "Texas children's medication algorithm project: Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder",
abstract = "OBJECTIVE: To revise and update consensus guidelines for medication treatment algorithms for childhood major depressive disorder based on new scientific evidence and expert clinical consensus when evidence is lacking. METHOD: A consensus conference was held January 13-14, 2005, that included academic clinicians and researchers, practicing clinicians, administrators, consumers, and families. The focus was to review, update, and incorporate the most current data to inform and recommend specific pharmacological approaches and clinical guidance for treatment of major depressive disorder in children and adolescents. RESULTS: Consensually agreed on medication algorithms for major depression (with and without psychosis) and comorbid attention-deficit disorders were updated. These revised algorithms also incorporated approaches to address issues of suicidality, aggression, and irritability. Stages 1, 2, and 3 of the algorithm consist of selective serotonin reuptake inhibitor and norepinephrine serotonin reuptake inhibitor medications whose use is supported by controlled, acute clinical trials and clinical experience. Recent studies provide support that selective serotonin reuptake inhibitors in addition to fluoxetine are still encouraged as first-line interventions. The need for additional assessments, precautions, and monitoring is emphasized, as well as continuation and maintenance treatment. CONCLUSIONS: Evidence and expert clinical consensus support the use of selected antidepressants in the treatment of depression in youths. The use of the recommended antidepressant medications requires appropriate monitoring of suicidality and potential adverse effects and consideration of other evidence-based treatment alternatives such as cognitive behavioral therapies. Copyright 2007",
keywords = "Child and adolescent depression, Childhood psychopharmacology, Major depressive disorder, Medication algorithm, Suicidality",
author = "Hughes, {Carroll W.} and Emslie, {Graham J.} and Crismon, {M. Lynn} and Kelly Posner and Boris Birmaher and Neal Ryan and Peter Jensen and John Curry and Benedetto Vitiello and Molly Lopez and Shon, {Steve P.} and Pliszka, {Steven R.} and Trivedi, {Madhukar H.} and Joan Barcelona and Cindy Hopkins and Jensen, {Peter S.} and Robin Mallett and Sylvia Musquiz and Valerie Robinson and Susan Rogers and Steve Shon and Madhukar Trivedi and Sylvia Turner",
year = "2007",
month = "6",
doi = "10.1097/chi.0b013e31804a859b",
language = "English (US)",
volume = "46",
pages = "667--686",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Texas children's medication algorithm project

T2 - Update from Texas consensus conference panel on medication treatment of childhood major depressive disorder

AU - Hughes, Carroll W.

AU - Emslie, Graham J.

AU - Crismon, M. Lynn

AU - Posner, Kelly

AU - Birmaher, Boris

AU - Ryan, Neal

AU - Jensen, Peter

AU - Curry, John

AU - Vitiello, Benedetto

AU - Lopez, Molly

AU - Shon, Steve P.

AU - Pliszka, Steven R.

AU - Trivedi, Madhukar H.

AU - Barcelona, Joan

AU - Hopkins, Cindy

AU - Jensen, Peter S.

AU - Mallett, Robin

AU - Musquiz, Sylvia

AU - Robinson, Valerie

AU - Rogers, Susan

AU - Shon, Steve

AU - Trivedi, Madhukar

AU - Turner, Sylvia

PY - 2007/6

Y1 - 2007/6

N2 - OBJECTIVE: To revise and update consensus guidelines for medication treatment algorithms for childhood major depressive disorder based on new scientific evidence and expert clinical consensus when evidence is lacking. METHOD: A consensus conference was held January 13-14, 2005, that included academic clinicians and researchers, practicing clinicians, administrators, consumers, and families. The focus was to review, update, and incorporate the most current data to inform and recommend specific pharmacological approaches and clinical guidance for treatment of major depressive disorder in children and adolescents. RESULTS: Consensually agreed on medication algorithms for major depression (with and without psychosis) and comorbid attention-deficit disorders were updated. These revised algorithms also incorporated approaches to address issues of suicidality, aggression, and irritability. Stages 1, 2, and 3 of the algorithm consist of selective serotonin reuptake inhibitor and norepinephrine serotonin reuptake inhibitor medications whose use is supported by controlled, acute clinical trials and clinical experience. Recent studies provide support that selective serotonin reuptake inhibitors in addition to fluoxetine are still encouraged as first-line interventions. The need for additional assessments, precautions, and monitoring is emphasized, as well as continuation and maintenance treatment. CONCLUSIONS: Evidence and expert clinical consensus support the use of selected antidepressants in the treatment of depression in youths. The use of the recommended antidepressant medications requires appropriate monitoring of suicidality and potential adverse effects and consideration of other evidence-based treatment alternatives such as cognitive behavioral therapies. Copyright 2007

AB - OBJECTIVE: To revise and update consensus guidelines for medication treatment algorithms for childhood major depressive disorder based on new scientific evidence and expert clinical consensus when evidence is lacking. METHOD: A consensus conference was held January 13-14, 2005, that included academic clinicians and researchers, practicing clinicians, administrators, consumers, and families. The focus was to review, update, and incorporate the most current data to inform and recommend specific pharmacological approaches and clinical guidance for treatment of major depressive disorder in children and adolescents. RESULTS: Consensually agreed on medication algorithms for major depression (with and without psychosis) and comorbid attention-deficit disorders were updated. These revised algorithms also incorporated approaches to address issues of suicidality, aggression, and irritability. Stages 1, 2, and 3 of the algorithm consist of selective serotonin reuptake inhibitor and norepinephrine serotonin reuptake inhibitor medications whose use is supported by controlled, acute clinical trials and clinical experience. Recent studies provide support that selective serotonin reuptake inhibitors in addition to fluoxetine are still encouraged as first-line interventions. The need for additional assessments, precautions, and monitoring is emphasized, as well as continuation and maintenance treatment. CONCLUSIONS: Evidence and expert clinical consensus support the use of selected antidepressants in the treatment of depression in youths. The use of the recommended antidepressant medications requires appropriate monitoring of suicidality and potential adverse effects and consideration of other evidence-based treatment alternatives such as cognitive behavioral therapies. Copyright 2007

KW - Child and adolescent depression

KW - Childhood psychopharmacology

KW - Major depressive disorder

KW - Medication algorithm

KW - Suicidality

UR - http://www.scopus.com/inward/record.url?scp=34249305198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249305198&partnerID=8YFLogxK

U2 - 10.1097/chi.0b013e31804a859b

DO - 10.1097/chi.0b013e31804a859b

M3 - Article

VL - 46

SP - 667

EP - 686

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 6

ER -